Genetically engineered mouse models of neurodegenerative diseases

Nature Neuroscience

Volumn 5, Issue 7, 2002, Pages 633-639

  Wong, Philip C ^a   Cai, Huaibin ^a   Borchelt, David R ^a   Price, Donald L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; DISEASE SIMULATION; GENETIC ENGINEERING; MEDICAL RESEARCH; MOTOR NEURON DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPINAL MUSCULAR ATROPHY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; CELL SURVIVAL; DISEASE MODELS, ANIMAL; MICE; MOTOR NEURON DISEASE; MOTOR NEURONS; NEURODEGENERATIVE DISEASES; SUPEROXIDE DISMUTASE;

EID: 0036303818     PISSN: 10976256     EISSN: None     Source Type: Journal    
DOI: 10.1038/nn0702-633     Document Type: Review

References (98)

1. Alzheimer's disease: Genetic studies and transgenic models
2. Neurodegenerative taupathies: Human disease and transgenic mouse models
3. Expanding our understanding of polyglutamine diseases through mouse models
4. Prospects for new restorative and neuroprotective treatments in Parkinson's disease
5. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease
6. Genetic classification of primary neurodegenerative disease
7. Alzheimer's disease: Genes, proteins and therapy
8. Genetic neurodegenerative diseases: The human illness and transgenic models
9. Intranuclear inclusions and neuritic pathology in transgenic mice expressing a mutant N-terminal fragment of huntingtin
10. Filamentous nerve cell inclusions in neurodegenerative diseases
11. Polyglutamine diseases: Protein cleavage and aggregation
12. Alzheimer's disease. What is it, how many people have it, and why do we need to know?
13. Neuroplasticity failure in Alzheimer's disease: Bridging the gape between plaques and tangles
14. Mutant genes in familial Alzheimer's disease and transgenic models
15. The cholinergic deficit coincides with Aβ deposition at the earliest histopathologic stages of Alzheimer disease
16. Molecular structure of a fibrillar Alzheimer's Aβ fragment
17. Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease
18. New frontiers in Alzheimer's disease genetics
19. Clearing the brain's amyloid cobwebs
20. Purification and cloning of amyloid precursor protein β-secretase from human brain
21. Identification of a novel aspartic protease (Asp 2) as β-secretase
22. Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein
23. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
24. β-secretase cleavage of Alzheimer's amyloid precusor protein by the transmembrane aspartic protease BACE
25. The brain's susceptibility to amyloid plaques
26. BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein
27. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation
28. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
29. Candidate gene for the chromosome 1 familial Alzheimer's disease locus
30. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene
31. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo
32. Gamma-secretase, Notch, Aβ and Alzheimer's disease: Where do the presenilins fit in?
33. A portrait of Alzheimer secretases-new features and familiar faces
34. Aβ-generating enzymes: Recent advances in β- and γ-secretase research
35. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
36. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and secretase activity
37. Aph-2/Nicastrin: An essential component of gamma-secretase and regulator of notch signaling and presenilin localization
38. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid
39. A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease
40. 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation
41. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models
42. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
43. Tau filament formation in transgenic mice expressing P301L tau
44. Accelerated amyloid deposition in the brains of transgenic mice co-expressing mutant presenilin 1 and amyloid precursor proteins
45. β-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity
46. Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members
47. Presenilin is required for activity and nuclear access of notch in drosophila
48. Presenilin 1 is required for Notchl and Dll1 expression in the paraxial mesoderm
49. Mice lacking both presenilin genes exhibit early embryonic patterning defects
50. APP processing and synaptic plasticity in presenilin-1 conditional knockout mice
51. Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces
52. BACEI is the major β-secretase for generation of Aβ peptides by neurons
53. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation
54. BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: Implication for Alzheimer's disease therapeutics
55. A splice variant of β-secretase deficient in the amyloidogenic processing of the amyloid precursor protein
56. Photoactivated γ-secretase inhibitors directed to the active site convalently label presenilin 1
57. Embryonic lethality in mice homozygous for a processing-deficient allele of Notch 1
58. New protease inhibitors prevent γ-secretase-mediated production of Aβ40/42 without affecting Notch clevage
59. γ-secretase inhibitors repress thymocyte development
60. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease
61. Immunization with amyloid attenuates Alzheimer-disease-like pathology in the PDAPP mouse
62. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
63. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
64. A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
65. Neuronal death in amyotrophic lateral sclerosis is apoptosis: Possible contribution of a programmed cell death mechanism
66. From Charcot to Lou Gehrig: Deciphering selective motor neurons death in ALS
67. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2
68. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis
69. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation
70. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria
71. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions
72. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SODI mutants to motor neurons
73. Amyotrophic lateral sclerosis: Unfolding the toxicity of the misfolded
74. Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase
75. Protective effect of neurofilament NF-H overexpression in motor neuron disease induced by mutant superoxide dismutase
76. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
77. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase
78. Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase
79. Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading
80. Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis
81. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1
82. Formation of intermediate filament protein aggregates with disparate effects in two transgenic mouse models lacking the neurofilament light subunit
83. Pathogenesis of two axonopathies does not require axonal neurofilaments
84. Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant
85. Overexpression of neurofilament subunit NF-L and NF-H extends survival of a mouse model for amyotrophic lateral sclerosis
86. The neurobiology of childhood spinal muscular atrophy
87. Identification and characterization of a spinal muscular atrophy-determining gene
88. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy
89. The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis
90. Subcellular localization and axonal transport of the survival motor neuron (SMN) protein in the developing rat spinal cord
91. Reduced survival motor neuron (Smn) gene dose in mice leads to motor neuron degeneration: An animal model for spinal muscular atrophy type III
92. A mouse model for spinal muscular atrophy
93. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn-/- mice and results in a mouse with spinal muscular atrophy
94. Treatment of spinal muscular atrphy by sodium butyrate